The short version of Thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-29 and is reviewed periodically as new material appears.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
At least several thousand years ago, some humans developed a mutation in the MCM6 gene that keeps the LCT gene turned on even after breast feeding is stopped. Populations that are lactose intolerant lack this mutation. The LCT and MCM6 genes are both located on the long arm (q) of chromosome 2 in region 21. The locus can be expressed as 2q21. The lactase deficiency also could be linked to certain heritages and varies widely. A 2016 study of over 60,000 participants from 89 countries found regional prevalence of lactose malabsorption was "64% (54–74) in Asia (except Middle East), 47% (33–61) in eastern Europe, Russia, and former Soviet Republics, 38% (CI 18–57) in Latin America, 70% (57–83) in the Middle East, 66% (45–88) in northern Africa, 42% (13–71) in northern America, 45% (19–71) in Oceania, 63% (54–72) in sub-Saharan Africa, and 28% (19–37) in northern, southern and western Europe." According to Johns Hopkins Medicine, in the United States lactose intolerance is more common in Asian Americans, African Americans, Mexican Americans, and Native Americans. Analysis of the DNA of 94 ancient skeletons in Europe and Russia concluded that the mutation for lactose tolerance appeared about 4,300 years ago and spread throughout the European population. Some human populations have developed lactase persistence, in which lactase production continues into adulthood probably as a response to the benefits of being able to digest milk from farm animals.
The Republic of South Africa was established in 1961. The only change made to the composition of the Parliament was the substitution of the State President for the Queen. A few significant changes were made later:
==== Biological oxidation and carcinogenic activity ==== One way of understanding the carcinogenic effects of benzene is by examining the products of biological oxidation. Pure benzene, for example, oxidizes in the body to produce an epoxide, benzene oxide, which is not excreted readily and can interact with DNA to produce harmful mutations.
== Chemistry == While the molecular weight of nicotinamide riboside is 255.25 g/mol, that of its chloride salt is 290.70 g/mol. As such, 100 mg of nicotinamide riboside chloride provides 88 mg of nicotinamide riboside.
Sources: en.wikipedia.org
== General bibliography == Duane, H. D. Roller; Thilorier, M. (1952). "Thilyorier and the First Solidification of a "Permanent" Gas (1835)". Isis. 43 (2): 109–113. doi:10.1086/349402. JSTOR 227174. S2CID 144091865. Goroll, Allan H; Mulley, Albert G (2009). Primary Care Medicine: Office evaluation and management of the adult patient. Lippincott Williams & Wilkins. ISBN 978-0-7817-7513-7. Häring, Heinz-Wolfgang (2008). Industrial Gases Processing. Christine Ahner. Wiley-VCH. ISBN 978-3-527-31685-4. Retrieved 2009-07-31. Housecroft, Catherine; Sharpe, Alan G (2001). Inorganic chemistry. Harlow: Prentice Hall. p. 410. ISBN 978-0-582-31080-3. Retrieved 2009-07-31. Keyes, Conrad G (2006). Guidelines for Cloud Seeding to Augment Precipitation. American Society of Civil Engineers. ASCE Publications. ISBN 978-0-7844-0819-3. Verma, N. K.; Khanna, S. K.; Kapila, B. (2008). Comprehensive Chemistry for Class XI. New Delhi: Laxmi Publications. ISBN 978-81-7008-596-6. Retrieved 2009-07-31. McCarthy, Robert E. (1992). Secrets of Hollywood Special Effects. Boston: Focal Press. ISBN 978-0-240-80108-7. Mitra, Somenath (April 2004). Sample Preparation Techniques in Analytical Chemistry. Wiley-IEEE. ISBN 978-0-471-32845-2. Retrieved 2009-07-31. Treloar, Roy D. (2003). Plumbing Encyclopaedia (3rd ed.). Wiley-Blackwell. p. 175. ISBN 978-1-4051-0613-9. Retrieved 2009-07-31. Yaws, Carl (2001). Matheson Gas Data Book (7th ed.). McGraw-Hill Professional. ISBN 978-0-07-135854-5. 982 pages. Retrieved 2009-07-27.
=== Tempe bongkrèk === Tempe bongkrèk is a variety of tempeh from Central Java, notably Banyumas. It is prepared with coconut dregs. This type of tempeh served as a main source of protein in Java due to its inexpensiveness and has led to several cases of fatal food poisoning, as it occasionally gets contaminated with the bacterium Burkholderia gladioli, and the unwanted organism produces toxins (bongkrek acid and toxoflavin) from the coconut, besides killing off the Rhizopus fungus due to the antibiotic activity of bongkrek acid. Fatalities from contaminated tempe bongkrèk were once common in the area where it was produced. During 1930s, the Dutch East Indies government went through an economic depression, and this condition caused some of the people to make tempe bongkrek by themselves, instead of buying it directly from well-trained producers. As a result, the poisonings occurred frequently, reaching 10 to 12 a year. Dutch scientists W. K. Mertens and A. G. van Veen from the Eijkman Institute of Jakarta, started to find the cause of the poisoning in the early 1930s. The first outbreak of the bongkrek poisoning by tempe bongkrek was recorded by Dutch researchers; however, no further research to find the cause of the poisoning was conducted in 1895. They successfully identified the source of poisoning as a bacterium called Pseudomonas marginata. This bacterium, which is also named Burkholderia cocovenenans, caused the synthesis of a poisonous substance called bongkrek acid. B.
In January 1868, when the new port of Kobe opened east of Hyogo Port, the Kobe foreign settlement was established. In 1868, Englishman Edward Charles Kirby established the first slaughterhouse in Kobe, and in 1869, a sukiyaki restaurant called "Gekka-tei" opened there. According to a newspaper article in 1875, Kobe was the first place where meat eating was popular, with 800 cows slaughtered in a month. Next was Yokohama with 600, followed by Tokyo with 500, and Osaka and Nagoya with 300. The reputation of Wagyu beef as having a superior taste spread from the residents of the foreign settlement to the Japanese, and it was written in books of the time that "Wagyu beef has a better taste than foreign beef" and "there has never been beef as good as Kobe's beef". At the same time, however, it was also believed that Wagyu were superior to Western breeds for plowing use but inferior in milk and meat production, and their improvement was urgently needed. Between 1868, the year of the Meiji Restoration, and 1887, some 2600 foreign cattle were imported. At first, there was little interest in cross-breeding these with the native stock, but from about 1900, it became widespread. In 1900, the Japanese government established a committee to investigate the improvement of cattle breeding, and began a systematic crossbreeding program between Wagyu and Western breeds.
Sources: en.wikipedia.org
== P == P24 – package insert – palliative – palliative care – pancreas – pancreatitis – pancytopenia – pandemic – pap smear – papilloma – parallel track – parasite – parenteral – paresthesia – passive immunity – passive immunotherapy – pathogen – pathogenesis – PBMC – PCP – PCR – Pediatric AIDS Clinical Trial Group (PACTG) – pelvic inflammatory disease – peptide – perianal – perinatal – perinatal transmission – peripheral neuritis – peripheral neuropathy – persistent generalized lymphadenopathy – PGL – phagocyte – phagocytosis – pharmacokinetics – phase I trials – phase II trials – phase III trials – phase IV trials – photosensitivity – PHS – pituitary gland – placebo – placebo controlled study – placebo effect – plasma – plasma cells – platelets – PML – Pneumocystis jiroveci pneumonia (formerly Pneumocystis carinii or PCP) – POL – polymerase – polymerase chain reaction (PCR) – polyneuritis – polypeptide – polyvalent vaccine – post-exposure prophylaxis (PEP) – PPD test – pre-conception counseling – preclinical – precursor cells – prevalence – primary HIV infection – primary isolate – primaquine – proctitis – prodrome – prodrug – progressive multifocal leukoencephalopathy (PML) – prophylactic drug – prophylaxis – protease – protease inhibitors – protease-sparing regimen – proteins – protocol – protozoa – provirus – pruritus – pseudo-Cushing's syndrome – pseudovirion – PUBMED – pulmonary – purified protein derivative (PPD)
=== Interactions === Any drugs that are also ligands of CYP3A4 and CYP1A2 can potentially increase serum levels and potential for toxicity or decrease serum levels and the efficacy, depending on whether they induce or inhibit the enzymes, respectively. Drugs that may increase the chance of methemoglobinemia should also be considered carefully. Dronedarone and liposomal morphine are both absolutely a contraindication, as they may increase the serum levels, but hundreds of other drugs require monitoring for interaction.
The three substrates of this enzyme are D-glyceraldehyde 3-phosphate, phosphate (Pi), and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are 1,3-bisphosphoglyceric acid, reduced NADH, and a proton. The enzyme can use nicotinamide adenine dinucleotide phosphate as an alternative cofactor. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of a donor with NAD+ or NADP+ as an acceptor. The systematic name of this enzyme class is D-glyceraldehyde 3-phosphate:NAD(P)+ oxidoreductase (phosphorylating). Other names in common use include triosephosphate dehydrogenase (NAD(P)) (phosphorylating), and glyceraldehyde-3-phosphate dehydrogenase (NAD(P)) (phosphorylating).
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.